Search

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder with loci on chromosome 9q34.3 (TSC1) and chromosome 16p13.3 (TSC2). Genes for both loci have been isolated and characterized. Clinical symptoms of TSC include cortical tubers, subependymal nodules, mental retardation, seizures, autism, shagreen patches and angiofibromas on the skin, cardiac rhabdomyomas, retinal hamartomas, and angiomyolipomas in the kidneys. Several mutations have been reported in both TSC genes in patients mainly from the western and Japanese populations. However, there is no report on the mutation analysis of TSC genes in patients from the Indian population. We report here the mutational analysis of the TSC1 and TSC2 genes in 24 TSC families from India. Using PCR-SSCP and DNA sequence analyses, we have screened all 21 coding exons of the TSC1 gene and all 41 coding exons of the TSC2 gene in seven familial and 17 sporadic TSC cases. We have also sequenced promoters of both the TSC genes in 24 probands. We have identified a total of 12 mutations. Of these, seven mutations are novel. We have identified a single previously known deletion in the TSC1 gene. Of 11 mutations identified in the TSC2 gene, 3 are deletions, 2 are insertions, 3 are missense, 2 are splice site and 1 is a nonsense mutation. In addition, we have also detected three and eight variants/polymorphisms in the TSC1 and TSC2 genes respectively. Of these, three are novel SNPs. There was no correlation between the types of mutations (missense, nonsense, etc.) and the severity of the disease. As observed in the western and Japanese populations, the mutations were scattered across the TSC2 gene. DNA sequence analysis of promoter regions of both TSC genes in 24 families did not show any variation. (This work was financially supported by a grant from DBT, New Delhi to AK and SCG and a CSIR JRF to MA).

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder with loci on chromosome 9q34 (TSC1) and chromosome 16p13 (TSC2). Genes for both loci have been isolated and characterized. The promoters of both genes have not been characterized so far and little is known about the regulation of these genes. This study reports the characterization of the human TSC1 promoter region. We have used PCR methodology to isolate approximately 1.6 kb genomic DNA 5’ to the TSC1 cDNA. This sequence has directed a high level of expression of luciferase activity in both HeLa and HepG2 cells. Successive 5’ and 3’ deletion analysis has suggested that a ~587 bp region, from position +77 to -510 from the TSS (transcription start site), contains the promoter activity. Interestingly, this region contains no consensus TATA box or CAAT box. However, a 521 bp fragment surrounding the TSS exhibits the characteristics of a CpG island which overlaps with the promoter region. Electrophoretic mobility shift assay indicated interaction of the predicted transcription factors binding elements like GC-box, E-box and E2F binding element with the transcription factors, within the core promoter. The identification of the TSC1 promoter region will help in designing a suitable strategy to identify mutations in this region in patients who do not show any mutations in the coding regions. It will also help to study the regulation of the TSC1 gene and its role in tumorigenesis.

Tuberous sclerosis complex (TSC) is an autosomal dominant neuro-cutaneous disorder with loci on chromosome 9q34.3 (TSC1) and chromosome 16p13.3 (TSC2). Genes for both loci have been isolated and characterized. Pathologically, tuberous sclerosis complex is a disorder of cell proliferation, differentiation and migration. Clinical symptoms of TSC include cortical tubers, subependymal nodules, mental retardation, seizures, autism, shagreen patches and angiofibromas on the skin, cardiac rhabdomyomas, retinal hamartomas, ungual and peringual fibromas, and cysts and angiomyolipomas in the kidneys. More than 350 mutations have been reported in both TSC genes in patients mainly from the western and Japanese populations. However, there is no report on the mutation analysis of TSC genes in patients from the Indian population. We report here the mutational analysis of the TSC2 gene in 23 TSC families from India. Using PCR-SSCP and DNA sequence analyses, we have screened all 41 exons and promoter region of the TSC2 gene in seven familial and 16 sporadic TSC cases. We have identified a total of 12 mutations representing 25% and 75% of familial and sporadic cases respectively. Of these, eight mutations are novel. Of 12 mutations, 3 are deletions, 2 are insertions, 4 are missense, 2 are splice site and 1 is a nonsense mutation. In addition, we have also detected nine single-nucleotide polymorphisms (SNPs) in the TSC2 gene. Of these three are novel SNPs. There was no correlation between the types of mutations (missense, nonsense, etc.) and the severity of the disease. The mutations were found to be distributed across the gene without any clustering, suggesting that mutation analysis requires scanning of the complete coding sequence of the TSC2 gene (This work was financially supported by a grant from DBT, New Delhi to AK and SCG and a CSIR JRF to MA)

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder with loci on chromosome 9q34 (TSC1) and chromosome 16p13.3 (TSC2). Genes for both loci have been isolated and characterized. During the present study, we have used the PCR methodology to isolate approximately 1.6 kb of the genomic sequence, 5' to the published TSC1 cDNA. This sequence directed a high level of luciferase activity in both Hela and HepG2 cells. Successive 5' and 3' deletion analysis suggested that ~300 bp region, from position -254 to -547 from the published 5' end of the TSC1 cDNA, contained the promoter activity. Interestingly this region contained no consensus TATA box or CAAT box, but a variant of TATA box (CATAAA) was found at a position -194 from the published 5' end of TSC1 cDNA. The Sp1 transcription factor binding sequence, GGCGGG, is found at three positions -207, -322 and -341 which is commonly seen in promoters of viral and cellular house keeping genes. In addition, binding sites for several other transcription factors, namely HNF4, MYCMAX, WT1, AML1 PAX6, FREAC2, MZF1, GATA3, ZBP89 were also found in the promoter region. The identification of the TSC1 promoter region will help in designing a suitable strategy to identify mutations in this region in patients who did not show any mutations in the coding regions. It will also help to study the mechanism of regulation of TSC1 gene (Financial assistance from DBT and CSIR is gratefully acknowledged).